Technology evaluation: Gene therapy (FGF-5), Vical

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 2, 1999, Pages 260-265

  Li, Kai ^a   Stewart, Duncan J ^b   Ward, Harry J ^a  

^a KING DREW MEDICAL CENTER   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 5; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; GENE THERAPY; GENE TRANSFER; HEART; HEART MUSCLE CELL; HUMAN; ISCHEMIC HEART DISEASE; NEPHROTOXICITY; PROTEIN EXPRESSION; TISSUE OXYGENATION;

ANIMALS; CLINICAL TRIALS; FIBROBLAST GROWTH FACTOR 5; FIBROBLAST GROWTH FACTORS; GENE THERAPY; HUMANS; MYOCARDIAL ISCHEMIA; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

ANIMALIA;

EID: 0033004102     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Vical's melanoma gene therapy trial. Scrip (1993) 1797:25.
2. Vical Inc. Form 10-K (1994).
3. Liang X, Hartikka J, Sukhu L, Manthorpe M, Hobart P: Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Gene Ther (1996) 3(4):350-356.
4. Wheeler CJ, Sukhu L, Yang G, Tsai Y, Bustamente C, Felgner P, Norman J, Manthorpe M: Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim Biophys Acta Biomembr (1996) 1280(1):1-11.
5. Felgner PL, Tsai YJ, Sukhu L, Wheeler CJ, Manthorpe M, Marshall J, Cheng SH: Improved cationic lipid formulations for in vivo gene therapy. Ann Ny Acad Sci (1995) 772:227-231.
6. Felgner PL: The evolving role of the liposome in gene delivery. J Liposome Res (1995) 5(4):725-734.
7. Marquet M, Horn N, Meek J, Budahazi G: Production of pharmaceutical grade plasmid DNA for gene therapy. J Cell Biochem Suppl (1995) 21:397.
8. Doh SG, Hartikka J, Vahlsing HL, Cornefert-Jensen F, Manthorpe M: Intramuscular injection of plasmid DNA: Spatial-temporal profile of reporter gene expression. J Cell Biochem Suppl (1995) 21:391.
9. Liang X, Kuwahara R, Hobart P: Enhanced and switchable expression systems for gene-transfer. J Cell Biochem Suppl (1995) 21:379.
10. Hobart P, Liang X, Margalith M, Bamhart K, Abai A, Kuwahara Rundell A, Nolasco M, Sawdey M, Hartikka J, Manthorpe M, Marrow J, Norman J: Designing plasma DNA vectors to express therapeutic levels of protein in vivo. J Cell Biochem Suppl (1995) 21:377.
11. Barnhart KM, Liang X, Hartikka J, Hobart P: Matrix attachment regions as transcription enhancing elements in plasmids designed for in vivo human gene therapy. J Cell Biochem Suppl (1995) 21:128.
12. Felgner PL, Tsai YJ, Sukhu L, Wheeler CJ, Manthorpe M, Marshall J, Cheng SH: Improved cationic lipid formulations for in vivo gene therapy. Ann Ny Acad Sci (1995) 772:126-139.
13. Rhodes GH, Abai AM, Margalith M, Kuwahara Rundella A, Morrow J, Parker SE, Dwarki VJ: Characterization of humoral immunity after DNA injection. Dev Biol Stand (1994) 82:229-236.
14. Meek J, Hom N, Budahazi G, Marquet M: Production of pharmaceutical-grade plasmid DNA from fermentor to vial for use in gene therapy. Pharm Res (1994) 11(10):92.
15. Tsai Y, Felgner J, Graves S, Marquet M, Felgner P: Prototype single vial cationic lipid-DNA formulations, for direct in vivo gene delivery. Pharm Res (1994) 11(10):78.
16. Felgner PL: Direct administration of purified genes in vivo. Aids Res Hum Retroviruses (1994) 10(1):20.
17. Felgner PL: Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides. Adv Drug Deliv Rev (1990) 5(3):163-187.
18. Vical Inc: Vical Incorporated announces issuance of core technology patent. Press Release December (1996).
19. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465-1468.
20. Haynes JR, McCabe DE, Swain WF, Widera G, Fuller JT: Particle-mediated nucleic acid immunization. J Biotechnol (1996) 44(1-3):37-42.
21. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable tranduction of nondividing cells by a lentiviral vector. Science (1996) 272(5259):263-267.
22. Vical Inc: Merck licenses vical's "naked" DNA technology to deliver certain growth factors. Press Release September 12 (1997).
23. Vical/Merck growth factor delivery deal. Scrip (1997) 2269:8.
24. Rhone-Poulenc Rorer Inc: Rhone-Poulenc Rorer Licenses Vical's "Naked" DNA Technology To Treat Neurodegenerative Diseases. Press Release October (1997).
25. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfeld K, Weir LE: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF-165 in patient with ischemic limb. Lancet (1996) 348:370-374.
26. Lazarous DF, Shou M, Scheinowitx M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation (1996) 94:1074-1082.
27. Lynch CM: New prospects for cardiovascular gene therapy. Exp Opin Invest Drugs (1997) 6(11):1691-1696.
28. Merck To Pay Vical $35M For Naked DNA Technology. Bioworld Week (1997) 5(38):2.
29. Verdier AS, Mattel MG, Lovec H, Hartung H, Goldfarb M, Birnbaum D, Coulier F: Chromosomal mapping of two novel human FGF gene, FGF11 and FGF12. Genomics (1997) 40:151-154.
30. Lovec H, Hartung H, Verdier AS, Mattel MG, Birnbaun D, Goldfarb M, Coulier F: Assignment of FGF-13 to human chromosome band Xq21 by in situ hybridization. Cytogenet Cell Genet (1997) 76:183-184.
31. Zhan X, Bates B, Hu X, Goldfarb M: The human FGF5 gene encodes a novel protein related to fibroblast growth factors. Mol Cell Biol (1988) 8:3487-3497.
32. Slavin J: Fibroblast Growth Factors: at the heart of angiogenesis. Cell Biol Int (1995) 19:431-444.
33. Gorlin RJ: Fibroblast growth factors, their receptors and receptor disorders. J Craniomaxillofac Surg (1997) 25:69-79.
34. Thompson JA, Anderson KD, KiPierto JM, Zweibel JA, Zametta M, Anderson WF, Maciag T: Site directed neovessel formation in vivo. Science (1988) 241:1349-1352.
35. Thompson JA, Haudenschild CC, Anderson KD, DiPierto JM, Anderson WF, Maciag T: Heparin binding in growth factor 1 induces the formation of organoid neovascular structure in vivo. Proc Natl Acad Sci USA (1989) 86:7928-7932.
36. Unger EF, Shou M, Sheffield CD, Hodge E, Jaye M, Epstein SE: Extracardiac to coronary anastamose support regional left ventricular function in dogs. Am J Physiol (1993) 264:H1567-H1574.
37. Muhlhauser J, Pill R, Merrill MJ, Meada H, Passaniti A, Crystal RG, Capogrossi MC: In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or non-secreted forms of acidic fibroblast growth factor. Hum Gene Ther (1995) 6:1457-1465.
38. Harada K et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest (1994) 94:623-630.
39. Weihrauch D, Arras M, Zimmermann R, Schaper J: Importance of monoccytes/macrophages and fibroblasts for healing of micronecroses in porcine myocardium. Mol Cell Biochem (1995) 147:13-19.
40. Unger EF, Banai S, Shou M, Lazarous DF, Jaklisch MT, Scheinowitz M, Correa R, Klinbeil C, Epstain SE: Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol (1994) 266:H1588-H1595.
41. Lopex JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Caputo RP, Carrozza JP, Douglas PS, Sellke FW, Simons M: Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp The r(1997) 282:385-390.
42. Giordano FJ, Ping PP, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med (1997) 2:534-539.
43. Yanagisawa-Miwa A, Uchida Y, Nkamura F, Tamaru T, Kido H, Kamijo T, Sugimoto T, Kaji K, Utsuyama M, Kurashima C: Salvage of infarcted myocardium by anglogenic action of basic fibroblast growth factor. Science (1992) 257:1401-1403.
44. Unger EF, Banai S, Shou M, Ajsklitsh M, Hodge E, Correa R, Jaye M, Epstein SE: A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res (1993) 27:785-791.
45. Banai S, Jaklitsch MT, Casscells W, Shou M, Shrivastav S, Correa R, Epstein SE, Unger EF: Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res (1991) 69:76-85.
46. Buttrick PM, Kass A, Kitsis RN, Kaplan ML, Leinwand LA: Behavior of genes directly injected into the rat heart in vivo. Circ Res (1992) 70:193-198.
47. Lin H, Parmacck MS, Morle G, Bolling S, Leiden JM: Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation (1990) 82:2217-2221.
48. von Harsdorf R, Schott RJ, Shen YT, Vatner SF, Mandavi V, Nadal-Ginard B: Gene injection into canine myocardium as a useful model for studying gene expression in the heart of large mammals. Circ Res (1993) 72:688-695.
49. Li K, Welikson R, Vikstrom K, Leinwand LA: Gene expression in mouse heart following DNA injection. J Mol Cell Cardiol (1997) 27:1499-1504.
50. Buzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T: Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res (1993) 73:1202-1207.
51. Muhlharser J, Merrill MJ, Pili R, Maeda H, Bacic M, Bewig B, Passaniti A, Edwards NA, Crystal RG, Capogrossi MC: VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res (1995) 77:1077-1086.
52. Li K, Buvoli M, Welikson RE, Vikstrom KL, Leinwand LA: Advances in cardiovascular gene transfer Cardiologia (1997) 42:39-46.
53. Kass-Eisler A, Falck-Pedersen E, Alvira M, Rivera J, Buttrick PA, Wittenberg BA, Cipriani A, Leinwand LA: Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA (1993) 90:11498-11502.
54. Ware JA, Simon M: Angiogenesis in ischemic heart disease. Nat Med (1997) 3:158-164.
55. Safi J Jr, Gloe TR, Riccioni T, Kovesdi I, Capogrossi MC: Gene therapy with anglogenic factors: A new potential approach to the treatment of ischemic diseases. J Mol Cell Cardiol (1997) 29:2311-2325.
56. Kuwabara K, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA (1995) 92:4606-4610.
57. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y: Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol (1994) 267:H1948-H1954.
58. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G: Upregulation of vascular endothellal growth factor expression by transient ischemia in rat heart Cardiovasc Res (1994) 28:1176-1179.
59. Leinwand LA, Leiden JM: Gene transfer into cardiac myocytes in vivo. Trends Cardiovasc Med (1991) 1:271-276.
60. Acsadi G, Dickson G, Love DR, Jani A, Walsh FS, Gurusinghe A, Wolff JA, Davies KE: Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature (1991) 352:815-818.
61. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA: Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA (1994) 91:9519-9523.
62. Tsurumi Y, Takeshita S, Chen D, Keamey M, Rossow ST, Passeri J, Horowitz JR, Symes JF, Isner JM: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation (1996) 94:3281-3290.
63. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ: Gene transfer and vascular disease. Cardiovasc Res (1994) 28:445-455.
64. Nabel EG: Gene therapy for cardiovascular disease. Circulation (1995) 91:541-548.
65. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P: Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest (1992) 90:626-630.
66. Barr E, Leiden JM: Somatic gene therapy for cardiovascular disease: recent advances. Trends Cardiovasc Med (1994) 4:57-63.
67. Fisher K, Choi H, Burda J, Chen SJ, Wilson JM: Recombinant adenovirus deleted to all viral genes for gene therapy of cystic fibrosis. Virology (1997) 217:11-22.
68. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA (1996) 93:5731-5736.
69. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest (1997) 99:2625-2634.
70. Goldfarb M: Functions of fibroblast growth factors in vertebrate development. Cytokine Growth Factor Rev (1996) 7:311-325.
71. Vical Inc: Vical announces third quarter 1998 financial results. Press Release November (1998).
72. Lewis BS, Flugelman MY, Weisz A, Keren TALI, Schaper W: Angiogenesis by gene therapy: a new horizon for myocardial revascularization? Cardiovasc Res (1997) 35(3):490-497.
73. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM: Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circ (1998) 98:2800-2803.